Analystreport

BioCryst Pharmaceuticals (NASDAQ:BCRX) is now covered by analysts at TD Cowen. They set a "buy" rating and a $30.00 price target on the stock.

BioCryst Pharmaceuticals, Inc.  (BCRX) 
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: biocryst.gcs-web.com/investor-relations